Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.50 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.50 |
| ▸ | IDH1 | O75874 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991270 | 0.83 | POLB (0.51) | KCNA5KCNE1IDH1ALDH1A1KCNH2 | |
| SCHEMBL1514881 | 0.83 | SLC6A4 (0.55) | KCNA5KCNE1ALDH1A1KCNH2CYP2D6 | |
| SCHEMBL9933670 | 0.83 | SLC6A4 (0.55) | KCNA5KCNE1ALDH1A1KCNH2CYP2D6 | |
| SCHEMBL8557410 | 0.76 | L3MBTL1 (0.51) | KCNA5KCNE1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL1514908 | 0.76 | GPR119 (0.50) | ACHE | |
| SCHEMBL9934875 | 0.76 | GPR119 (0.50) | ACHE | |
| SCHEMBL38663417 | 0.76 | GPR119 (0.50) | ACHE | |
| SCHEMBL18705018 | 0.75 | IDH1 (0.48) | KCNA5KCNE1IDH1ALDH1A1 | |
| SCHEMBL9963447 | 0.74 | IDH1 (0.47) | KCNA5KCNE1IDH1ALDH1A1KCNH2 | |
| SCHEMBL16230438 | 0.74 | KCNA5 (0.42) | KCNA5KCNE1IDH1ALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | KCNA5 865/4885KCNE1 1207/4885IDH1 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.